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Abstract
Background: Non-tuberculous mycobacteria have long been identified as capable of causing human disease and
the number at risk, due to immune-suppression, is rising. Several reports have suggested incidence to be
increasing, yet routine surveillance-based evidence is lacking. We investigated recent trends in, and the
epidemiology of, non-tuberculous mycobacterial infections in England, Wales and Northern Ireland, 1995-2006.
Methods: Hospital laboratories voluntarily report non-tuberculous mycobacterial infections to the Health Protection
Agency Centre for Infections. Details reported include age and sex of the patient, species, specimen type and
source laboratory. All reports were analysed.
Results: The rate of non-tuberculous mycobacteria reports rose from 0.9 per 100,000 population in 1995 to 2.9 per
100,000 in 2006 (1608 reports). Increases were mainly in pulmonary specimens and people aged 60+ years. The
most commonly reported species was Mycobacterium avium-intracellulare (43%); M. malmoense and M. kansasii
were also commonly reported. M. gordonae showed the biggest increase over the study period rising from one
report in 1995 to 153 in 2006. Clinical information was rarely reported.
Conclusions: The number and rate of reports increased considerably between 1995 and 2006, primarily in older
age groups and pulmonary specimens. Increases in some species are likely to be artefacts but real changes in
more pathogenic species, some of which will require clinical care, should not be excluded. Enhanced surveillance
is needed to understand the true epidemiology of these infections and their impact on human health.
Background
The non-tuberculous mycobacteria (NTM), mycobac-
teria other than members of the Mycobacterium tuber-
culosis complex and M. leprae, have been documented
since the 1950s as organisms capable of causing human
disease [1], receiving greater clinical recognition as the
incidence of tuberculosis fell [2]. Over 100 species of
NTM have been identified but only around 15 are con-
sidered pathogenic in humans [3]. While NTM can
cause pulmonary, lymph node, skin and disseminated
disease in humans, many species are found ubiquitously
in environmental reservoirs and in various domestic and
wild animals and are therefore frequently isolated from
clinical samples due to contamination. In general, NTM
only cause disease in immunocompromised individuals,
which is relative in small children, or actual, e.g. in
those with HIV infection or structural tissue damage in
the lungs due to chronic obstructive pulmonary disease
(COPD), cystic fibrosis, or scarring due to a number of
conditions including tuberculosis. These infections can
be difficult to treat, are often reported as having in-vitro
resistance on single antibiotic testing, although synergy
with combinations has been shown [4], and can compli-
cate the diagnosis of tuberculosis. NTM infections are
not normally transmissible between humans.
Determining the clinical relevance of NTM isolates can
be difficult and can depend on a combination of the site
from where the sample was taken, the number of isola-
tions, and the species involved, as well as clinical symp-
toms and any predisposing conditions of the patient [5].
M. avium-intracellulare often presents as disseminated
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node disease in young children and pulmonary disease
mimicking tuberculosis in COPD patients. M. kansasii is
also commonly associated with pulmonary infections clo-
sely resembling tuberculosis, both clinically and radiolo-
gically, and may be misdiagnosed [7]. M. malmoense may
be clinically significant regardless of the site of infection
[8] which is usually pulmonary, again mimicking tuber-
culosis, as does M. xenopi. M. abscessus has been
described as a prevalent NTM infection in children with
cystic fibrosis [9]. M. gordonae is normally considered
non-pathogenic and is often found as a laboratory con-
taminant but does sometimes cause disease, even in
immunocompetent patients [10].
The most recent study of national surveillance data for
England and Wales by Lamden et al. reported an increase
in NTM reports from 123 in 1982 to 392 in 1994 [11].
Most of this increase was attributed to an increase in
M. avium-intracellulare infections, notably in the form
of disseminated disease and in males aged 25 to 44 years.
Other NTM infections in this study were most com-
monly reported in those aged 45 and over. Prior to the
increases in HIV infection and AIDS, most NTM infec-
tions were found in those aged 50-59 with pre-existing
lung conditions or occupational exposure to dusts [12].
Several reports from other western countries have
suggested the incidence of NTM disease is increasing
[12-14] but there is currently a lack of routine, national
surveillance based evidence to support this [12]. The
number at risk of NTM infection due to immune-sup-
pression is rising owing to factors such as more HIV
diagnoses, new treatments for pre-existing conditions
such as cystic fibrosis and malignancies, and an increas-
ingly elderly population with significant levels of COPD
and structural lung disease. This study investigated
recent trends in, and described the epidemiology of,
NTM infections in England, Wales and Northern
Ireland between 1995 and 2006.
Methods
Hospital laboratories in England, Wales and Northern
Ireland voluntarily report mycobacterial infections, as part
of routine reporting of all infectious agents, to the Health
Protection Agency (HPA) Centre for Infections. Patient
samples identified by local hospital laboratories as positive
for mycobacteria are forwarded to specialist reference
laboratories that will identify the species and report back
to the local laboratory. All isolates deemed clinically signif-
icant by the source hospital are reported to the HPA.
Details routinely reported include age and sex of the
patient, species, specimen type and source laboratory. All
reports of NTM between 1995 and 2006 were analysed.
Incidence rates and percentage change were calculated
for each species of NTM reported. Demographic
information was analysed for all NTM as a whole, with
further detailed analyses for the three most commonly
reported species and the species showing the biggest
percentage increase over the study period. Clinical infor-
mation in comments fields was also reviewed for these
species to assess the clinical significance of reports and
consider associated risk factors for infection.
Office for National Statistics mid-year population esti-
mates were used for the calculation of rates of NTM
infection per 100,000 population. Analyses by region
were completed based on the region of the reporting
source laboratory. Site of disease was inferred from spe-
cimen type; as in some cases NTM were isolated from
more than one site, the total number of reports by site
may exceed the total numbers reported otherwise.
The Health Protection Agency has Patient Information
Advisory Group approval to hold and analyse national
surveillance data for public health purposes under Sec-
tion 60 of the Health and Social Care Act 2001.
Results
The rate of all NTM reports increased from 0.9 per
100,000 population in 1995 to 2.9 per 100,000 in 2006
(Table 1). Except from 2002 to 2003, numbers increased
annually, rising to 1608 reports in 2006, a 250% increase
compared to 1995. The most commonly reported spe-
cies was M. avium-intracellulare, accounting for 43% of
all reports, followed by M. malmoense (14%) and M.
kansasii (13%); M. gordonae showed the biggest percen-
tage increase in reports over the study period. Changes
in rates for these four species are shown in Figure 1. M.
abscessus was not reported prior to 2000, M. peregrinum
was not reported before 2004, and an increasing number
of isolates were reported without a species name.
Most NTM reports were in males (6518/10863, 60%)
and the rate of reports was consistently higher each year
in males compared to females (3.3 v 2.4 per 100,000 popu-
lation in 2006). The majority of reports were from people
aged 60 years or over (5717/10824, 53%). The greatest
numbers of reports were from the North East (2126/
11039, 19%) and London (1972/11039, 18%); the highest
rate of reports in 2006 was from the North East (10.3 per
100,000) followed by Northern Ireland and London (4.9
and 4.4 per 100,000 respectively). The biggest increases in
reports from 1995 to 2006 were in Northern Ireland
(1129%) and the North East (1100%). Eighty-one percent
(8832/10895) of reports were from a pulmonary site. How-
ever, this varied with age: in those aged under 15, 83%
(423/507) of reports were extra-pulmonary.
M. avium-intracellulare
T h er a t eo fr e p o r t so fM. avium-intracellulare rose
three-fold from 0.4 per 100,000 in 1995 to 1.2 per
100,000 in 2006 (Table 1, Figure 1). Increases were seen
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(from 0.7 per 100,000 to 3.6 per 100,000 - Figure 2).
The increase was also more pronounced in pulmonary
sites, rising from 45% of reports (113/251) in 1995 to
80% (603/757) in 2006. The percentage of reports from
blood specimens declined from 28% (71/251) to 3% (21/
757) in the same period.
Useful clinical comments were available for just 8%
(363/4732) of reports. Of these, HIV/AIDS, chronic
respiratory illness, cystic fibrosis and cancer were
Table 1 Non-tuberculous mycobacteria reports and rates by species, England, Wales and Northern Ireland, 1995, 2000,
2006
1995 2000 2006
Species Total number (1995-2006)
Number Rate
per
100,000
Number Rate
per
100,000
Number Rate
per
100,000
M. avium-intracellulare 225 0.4 360 0.7 649 1.2 4732
M. malmoense 101 0.2 145 0.3 130 0.2 1510
M. kansasii 71 0.1 129 0.2 152 0.3 1380
M. xenopi 33 0.1 50 0.1 117 0.2 827
M. chelonae 5 0.0 42 0.1 117 0.2 708
M. fortuitum 6 0.0 27 0.1 90 0.2 518
M. gordonae 1 0.0 12 0.0 153 0.3 516
M. marinum 14 0.0 27 0.1 27 0.0 274
M. abscessus 0 0.0 1 0.0 60 0.1 172
M. peregrinum 0 0.0 0 0.0 30 0.1 69
M. terrae 0 0.0 2 0.0 4 0.0 33
M. szulgai 1 0.0 0 0.0 1 0.0 30
M. fortuitum/chelonae group 0 0.0 0 0.0 4 0.0 23
M. scrofulaceum 0 0.0 1 0.0 1 0.0 15
M. flavescens 0 0.0 0 0.0 0 0.0 1
Unnamed species 2 0.0 5 0.0 73 0.1 231
Total 459 0.9 801 1.5 1608 2.9 11039
Figure 1 Rates of non-tuberculous mycobacteria reports (selected species), England, Wales and Northern Ireland, 1995-2006.
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of reports respectively.
M. malmoense
M. malmoense was the second most commonly reported
s p e c i e so v e rt h es t u d yp e r i o d( T a b l e1 ) .T h er a t eo f
reports was stable at between 0.2 and 0.3 per 100,000
(Figure 1), a mean of 126 per year. The majority of
reports were in men (939/1488, 63%) and in people
aged 45 years and over (1255/1480, 85%); just 5% (77)
occurred in young adults aged 15-44 years and 10%
(148) were in those under 15 years. Ninety percent
(1266/1404) of infections were from pulmonary sites.
Where information was available in clinical comments
(5%, 73/1510), chronic respiratory illness was most com-
monly reported (24, 33%), followed by cancer (4, 5%).
M. kansasii
T h er a t eo fM. kansasii reports rose from 0.1 per
100,000 in 1995 to 0.3 per 100,000 in 2005 (Table 1,
Figure 1). Increases were seen in both sexes, but mainly
in those aged 45 and over. Ninety-two percent (1282/
1389) of reports were from a pulmonary site. Chronic
respiratory illness was again the most commonly
reported clinical comment (20/69, 29%) where informa-
tion was available (69/1380, 5%).
M. gordonae
Reports of M. gordonae increased from just 1 in 1995 to
153 in 2006, when it was the second most commonly
reported species and at a rate of 0.3 per 100,000
population (Table 1, Figure 1). In contrast to the trends
seen by region for all NTM, reports were most commonly
from Yorkshire and the Humber (133/516, 26%), with just
0.4% (2/516) coming from the North East. Sixty-one per-
cent of reports were in males (307/505). Although the
increase was largest in those over 65 years old (rising to
0.8 per 100,000 in 2006) and in pulmonary sites, numbers
increased in both sexes, across all age groups and in both
pulmonary and extra-pulmonary infections. Where clinical
comments were present (41/516, 8%), 49% (20/41) men-
tioned chronic respiratory illnesses.
Discussion
Main findings
The number and rate of NTM reports increased consid-
erably between 1995 and 2006, continuing the trend
reported previously [11]. Increases were seen across
many species reported, but were most noticeable in M.
avium-intracellulare and M. gordonae.T h er i s ei na l l
NTM was predominantly in pulmonary sites in those
over 60 years of age.
Sixty percent of all NTM reports were in men and
rates were consistently higher in men across all years.
Men may be more susceptible to NTM infection due to
higher historical rates of smoking and COPD. A higher
index of suspicion of tuberculosis in men, and therefore
an increased submission of investigative samples from
men, may also have contributed to this finding if NTM
were found as a consequence.
Previous increases in M. avium-intracellulare infec-
tions have been linked to increases in HIV/AIDS [6].
Figure 2 Rates of M. avium-intracellulare reports by age group (years), England, Wales and Northern Ireland, 1995-2006.
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therapy (HAART) in the mid-1990s has since led to
greater immune-competence in these patients. The
increases observed here were in older age groups and
mainly from pulmonary sites, inconsistent with dissemi-
nated infection in HIV/AIDS patients; the percentage of
reports from blood specimens also fell considerably. The
changes seen may therefore be associated with increases
in immune-suppressive therapies for other conditions in
older age groups.
Ninety-two per cent of M. kansasii reports were from
pulmonary specimens, which is consistent with the pre-
sentation of such infections resembling pulmonary
tuberculosis [7]. The increases seen in the number of
pulmonary M. kansasii reports may have important
implications for both patients and public health as treat-
ment and contact tracing for tuberculosis may be inap-
propriately/unnecessarily initiated. This highlights the
need for prompt submission of specimens for identifica-
tion, and awaiting speciation prior to large-scale contact
investigation [15].
Interpreting the trends
The HPA’s reporting guidelines state that only clinically
significant isolates should be reported and these criteria
did not change over the study period, so a change in
guidelines cannot explain the observed trend. It is possi-
ble, however, that the guidelines have not been ade-
quately followed and so the increases observed may not
reflect clinical significance. The correct reporting of
only clinically significant isolates appeared to vary by
region and species - just 1% of all M. gordonae reports,
rarely considered clinically significant, came from the
North East, yet the region accounted for the highest
proportion of reports of all NTM, suggesting greater
adherence to guidelines in this region. The relatively
small increase in M. malmoense reports, which guide-
lines state may always be considered clinically signifi-
cant, appears to indicate that some of the larger
increases in other species, where clinical significance is
less defined, may be accounted for by increased ten-
dency of laboratories to report non-clinically significant
isolates.
In a region of the Netherlands, just 25% (53/212) of all
pulmonary NTM isolated met the American Thoracic
Society diagnostic criteria for clinical significance based
on a review of medical records [12,13], highlighting the
scope for over-reporting. However, this did vary by spe-
cies: just 1/48 (2%) of M. gordonae isolates were consid-
ered clinically relevant compared to 24/59 (41%) isolates
of M. avium, for example.
Changes in laboratory techniques may have contribu-
ted to increased detection of NTM as the use of auto-
mated liquid culture gradually became more widespread
over the study period. In the early 1990s, such methods
were considered expensive and impractical for many
laboratories [16] but by 2000, increasing numbers of
laboratories were purchasing such systems [17], and the
latest HPA standard operating procedures from 2006
state the use of automated liquid culture as the standard
recommendation [18]. Experience of the authors sug-
gests that M. gordonae and M. chelonae were rarely iso-
lated prior to the use of liquid culture media. Since this
change, moderate numbers have been isolated but very
few are clinically relevant and are more likely to be con-
taminants of samples, particularly where the patient has
no chest x-ray changes. The large increase in M. gordo-
nae reports was not specific to any particular age group,
sex or site and is likely to be associated with increased
detection and reporting of isolates that are not clinically
significant.
The introduction of DNA probe identification meth-
ods [17] may have contributed to increasingly specific
and accurate speciation. The apparent emergence of
some species, for example M. abscessus,a r ed u et o
changes in taxonomy. Other increases seen may be
linked to a rise in the number of samples submitted for
identification of M. tuberculosis as rates and awareness
of tuberculosis have increased (rates of tuberculosis in
England increased from 11.2 per 100,000 in 1999 to
15.4 per 100,000 in 2006) [19].
Limitations
Some duplicate reporting by local hospital laboratories
and specialist reference laboratories may be occurring,
leading to an artefactual rise, especially in the North
East. It is also possible that multiple isolations from the
same patient were reported and so the numbers of iso-
lates may not reflect numbers of patients. Having said
this, multiple isolates should impact only on the num-
bers and not on the trends observed, assuming the
numbers of samples submitted per patient has remained
similar.
The lack of clinical data accompanying most reports
did not allow us to assess their actual/true clinical sig-
nificance, and it was therefore not possible to interpret
whether trends were related to contamination or coloni-
sation rather than clinical disease.
Conclusions
Reports of NTM in England, Wales and Northern
Ireland continue to increase but the clinical significance
of this increase remains unknown. A number of infec-
tions inevitably require clinical care and a small propor-
tion may lead to inappropriate treatment/contact
investigation if tuberculosis is assumed. However, due to
the non-transmissible nature of these infections, they
have failed to attract the level of attention or policy
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information in surveillance data limits the interpretation
of the observed trends.
While artefactual changes may, at least for some spe-
cies, have contributed to the observed increase in NTM
reports, real changes in the more notable, pathogenic
species should not be excluded. Further study of specific
reports, involving a detailed assessment of patient notes,
is required to validate and understand the data observed.
The collection of detailed clinical data, through a dedi-
cated enhanced surveillance system, is needed to aid the
understanding of NTM epidemiology and the assess-
ment of the real impact of increasing reports on human
health.
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